Adis partnership with Amplion delivers biomarker data to AdisInsight users

Partnership to enrich drug and clinical trial content in the AdisInsight platformPartnership to enrich drug and clinical trial content in the AdisInsight platform

Heidelberg | New York, 4 October 2016

Adis, a leading global provider of drug information, has entered into a partnership with Amplion, market-leaders in biomarker information, to enrich drug and clinical trial content in the AdisInsight platform with curated biomarker data.

The new data is fully integrated into the AdisInsight platform meaning that users can perform quick or advanced searches across the data, view biomarker information within drug and trial profiles, and include it with exports and alerts. Existing customers will automatically benefit from the addition of biomarker data as part of their subscription.

Mirko Walter, Director of Product Management for Adis Business Intelligence states: “It is very important for us to work with a partner that shares our commitment to providing scientifically accurate content. The work that Amplion does in this space with BiomarkerBase is unparalleled and we are proud to be working with them to deliver an even more valuable service to our customers.”

Established in 2012, Amplion have quickly grown to dominate the global biomarker business intelligence market. Their flagship product, BiomarkerBase is the leading source of information about biomarkers used in drug development and diagnostic tests, tracking almost 80,000 biomarker uses worldwide by over 800 companies across 20 therapeutic areas.

“Working with Adis will allow us to distribute our information in a context that will help pharmaceutical and diagnostic companies better leverage biomarkers to triple clinical trial likelihood of approval and to improve top lines through improved product portfolio management,” says Amplion’s CEO, John Zicker. “As a growing company we are ecstatic to be working with such a strong partner.”

This exclusive combination of data sets will support greater efficiency in R&D programs as users will be able to identify key biomarkers associated with a drug and understand how they were used in clinical trials to improve outcomes, and to reduce timelines. The enriched data will also provide greater insights into drug and disease landscapes, helping companies to identify new opportunities.

Biomarkers play a vital role in drug development and therapy. During the clinical phases, they can cut trial timelines through the use of progression and predictive markers and increase likelihood of approval by refining patient selection. In addition, they can be used to identify new drug targets for research and development. In the clinic, biomarkers are critical to patient care with advanced diagnostic tools and the development of precision medicines tailored to individual patients.

Adis will also provide Amplion with granular drug information to enable more sophisticated analyses within BiomarkerBase. For example, users of BiomarkerBase will be able to organise their results by Drug Class, Mechanism of Action or Indication to assess how a biomarker fits within a therapy landscape. Users of AdisInsight will also have the option to follow links to BiomarkerBase to seek out further information.

Amplion is the leading biomarker business intelligence company, and its flagship product BiomarkerBase™, along with biomarker data mining and analytical services, deliver insights that inform key strategic decisions for drug and diagnostic test developers. Since 2012 Amplion has helped large and small companies alike make the best use of biomarkers in advancing precision therapeutics and next generation diagnostics.

Adis is part of Springer Nature, a leading global research, educational and professional publisher, home to an array of respected and trusted brands providing quality content through a range of innovative products and services. Springer Nature is the world’s largest academic book publisher, publisher of the world’s highest impact journals and a pioneer in the field of open research. The company numbers almost 13,000 staff in over 50 countries and has a turnover of approximately EUR 1.5 billion. Springer Nature was formed in 2015 through the merger of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media. Visit www.springernature.com and follow @SpringerNature.